July 29, 2024 12:54 PM EDT
People
Cell/Gene Tx
Manufacturing

Pfiz­er cuts 210 North Car­oli­na work­ers af­ter it of­fi­cial­ly dis­con­tin­ues failed Duchenne gene ther­a­py

Kyle LaHucik

Senior Reporter

Pfiz­er will end de­vel­op­ment on its ex­per­i­men­tal Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py af­ter a Phase 3 fail­ure last month, and plans to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

A service from the Financial Times